5:21 PM ET
8-K
Reverse Stock Split
Rallybio Reverse Stock Split
Rallybio announced a 1-for-2 reverse stock split effective November 20, 2026, reducing outstanding shares from 5.6 million to 2.8 million. The split is being executed in connection with its pending merger with Avenzo Therapeutics, Inc., after which the combined company will trade under the symbol AVZO. The final ratio was mutually determined by both companies following shareholder approval at the November 4, 2026, annual meeting.
- Counterparty
- Avenzo Therapeutics, Inc.